

For personal use only




**Wilsons
Drug and Device Conference
October 2023**

**Mark Harding
Senior Vice President
Global Marketing and R&D.**



Significant TAM:
Almost 1 billion people globally suffer from OSA^{1,2}

- OSA is highly prevalent and undiagnosed medical condition, associated with cardiovascular and metabolic diseases
- SOM's TAM continues to grow as national health bodies learn more about OSA and the long-term health risks of OSA



- Oral Appliance Therapy (OAT) is an effective alternative to CPAP for mild/ moderate OSA and is preferred by patients when they try both therapies.¹
- Greater compliance rates of OAT results in comparable improvements in quality-of-life and cardiovascular measures³
- However, today OAT only represents 10.6% of TAM for OSA devices.



SOM is the leading provider of OAT to treat OSA globally

- ~830,000 patients being treated by SOM OAT devices
- Global leader in the design, manufacture and distribution of OAT devices since inception 19 years ago
- Competitive differentiation via b-flex comfort liner that creates superior comfort and improved compliance to therapy.



SOM - only global player in OAT

- Operating in 28 countries (17 with direct sales teams) .
- 8 regional hubs delivering support to local dental and medical customers.
- ISO 13485 certified manufacturing facility in the Philippines. Upgrading to MDSAP level certification over the next 2 years.



Robust, clinical research is at the core

- SomnoMed's product suite and technology is based on long-running investment in research and development in Australia.
- High quality clinical research, real world evidence and health-economics provide the foundation for governments and insurers to use OAT as first line therapy (as in the Netherlands and Sweden).



Leading management team and board


- More than 100 years of collective medical device experience of senior management team.
- Highly engaged board and a passionate management team

1. A. V. Benjafield et. al. Estimation of the global prevalence and burden of OSA: a literature-based analysis. *Lancet Respiratory Medicine*. Aug 2019; 7(8): 687-698, Philips et.al Am J Respir Crit Care Med Vol 187, Iss. 8, pp 879-887,
2. U. Devaraj et. al. Undiagnosed OSA and Postoperative Outcomes: A Prospective Observation Study: *Respiration* (2017) 94(1): 18-25
3. H. U. Dissanayake et. al. Obstructive sleep apnea therapy for cardiovascular risk reduction-Time for a rethink? *Clinical Cardiology*. Dec 2021; 44(12): 1729-1738

Growth Track Record



Total Revenue (\$m)¹



1. Core SOM revenues only. Excludes revenues from Renew Sleep Services (RSS). RSS was in operation from FY17, and closed halfway through FY19

Rest Assure - Addressing barriers to OAT prescription




For personal use only



How does Rest Assure address OAT barriers?

For personal use only

SOM market research: Key barriers to prescribing OAT
242 Sleep Physicians - conducted in Oct 2019



A
Lack of night-time monitoring

- Currently physicians don't know if a patient has an oral device, if they're wearing it and if it's working. They know this with CPAP
- Rest Assure provides all night, every night monitoring of OAT treatment efficacy and adherence to therapy with a medical device customised for each patient

B
Lack of clinical evidence

- Current clinical evidence supporting OAT is based on small patient population studies. Limited real-world data.
- Rest Assure enables continuous large scale data collection via regional data registries, at much lower cost than clinical studies.
- Rest Assure will be integrated into clinical trials to demonstrate effective oral device design of SOM products

C
Reimbursement and cost

- For patients in therapy, over 5 years, CPAP is reimbursed 2-10 x the price of OAT (depending on the market).¹
- 50% of patients may not be using CPAP at 2 years.²
- Rest Assure will track compliance and provide objective, real world effectiveness (adherence and efficacy) data of OAT patients to insurance companies and payors **on their patients**

D
Lack of awareness of OAT as an alternative

- CPAP is considered the gold standard and the "go to" therapy to treat OSA
- Increasing focus on "personalised medicine" and involving patient in decision making
- Rest Assure will convince both physicians and patients of the effectiveness of OAT
- Rest Assure opens Direct to Patient marketing channel for SOM

1. SOM internal data.
2. Hwang D et al. PATTERNS OF LONG-TERM CPAP ADHERENCE: A 3-YEAR FOLLOW-UP FROM THE TELE-OSA STUDY, SLEEP, Volume 42, Abstract 0518, 2019

Intended market rollout strategy

Steps to market

Rest Assure submission to the US FDA

Completion of regulatory paperwork for CE Mark

**Rest Assure launched in a high-volume clinic in Europe
“Launch and Learn”**

Rollout to other high-volume customers in target Europe markets and Canada.

Rest Assure launch in other EU countries and US (pending FDA clearance)

Rest Assure launch in APAC

Rest Assure Marketing strategy

Launch

- Rest Assure will be marketed as a premium OAT product, where local reimbursement allows
- Rest Assure will launch first in countries where it is classified as a Class I medical device with supportive physician/ dental partners



Broader rollout (focus on US market)

- Rest Assure will seek 510(k) premarket authorisation from the US FDA with the submission based on an existing predicate device
- Will be launched at dental sleep clinics in the US that are paired with strong supporting sleep physician relationships/referrals

APAC

- Rest Assure classified as a Class IIa medical device by the TGA.

Rest Assure enables DTP marketing.



Pre-Rest Assure DTP pilots.

- Direct to Patient (DTP) campaigns in Facebook in US and ANZ conducted to test DTP systems (using Salesforce/ Marketo)
- Campaigns direct patients to “Find A Provider” on SOM website, linking patients with dentists using SOM devices
- Campaigns targeting OSA sufferers who have stopped using CPAP have positive ROI

Local DTP marketing (focus on US market)

- Local campaigns driving patients to dentists have been shown to increase dentist loyalty to SOM
- DTP marketing to users of Rest Assure to encourage them to “refer a friend” and leave testimonials
- Exploring DTP campaigns to current users of SOM devices to upgrade to Rest Assure

OSA Market Overview

Treatment landscape

3 primary treatment options currently available to treat Obstructive Sleep Apnea (OSA)

1

OAT

Oral Appliance Therapy (OAT) works by moving the mandible forward, opening the airway and removing any airflow restriction.

High compliance

Moderate efficacy

Low - moderate 5yr cost

Low invasiveness

2

CPAP

Continuous Positive Airway Pressure applies air pressure to the upper airway to keep the airway open to enable normal breathing while asleep.

Low - moderate compliance

High efficacy

Moderate 5yr cost

Moderate invasiveness

3

Surgical Procedures including Hypoglossal Nerve Stimulation

Invasive option considered as a last resort for severe OSA.

Moderate - high compliance

Moderate - high efficacy

Very high 5yr cost

High invasiveness

SomnoMed Overview

Market

Almost 1 billion people suffer from OSA globally. The most popular form of OSA treatment (CPAP) reports low compliance which impacts their overall effectiveness.

Uptake of OAT is driven by the acceptance, awareness and adoption of medical professionals prescribing the treatment.

SomnoMed mission

To advance the adoption, acceptance and treatment of oral sleep apnea therapies by patients, medical specialists, dentists and insurers

SomnoMed products

SomnoDent OAT devices



Current SomnoMed OAT devices have been used by ~830k patients globally

Rest Assure



SOM's OAT devices measure night to night compliance and efficacy, soon to be released to market

Market Opportunity

Growth opportunity

Raise awareness

- OAT is considered 2nd line therapy for mild-moderate OSA in most markets, with the OAT segment estimated to account for 10.6% of SOM's global TAM (CPAP largely taking the remaining market share)¹
- In markets where OAT devices are 1st line therapy for mild-moderate OSA (Sweden, The Netherlands), OAT has an equal market share with CPAP (~45%+)

Launch Rest Assure

- Rest Assure enables continuous monitoring and data capture from patients, addressing the lack of night-time monitoring - a key barrier to OAT prescription.
- Rest Assure will provide the market with real world evidence and data to demonstrate the effectiveness and comfort (adherence) of OAT, increasing:
 - Awareness, acceptance and adoption of OAT and the likelihood of Rest Assure being prescribed by physicians; and
 - The likelihood that Rest Assure is considered as first line therapy and reimbursed by payors.
 - Awareness of Rest Assure as an alternative to CPAP, especially where SOM can deploy DTP marketing.

1. In the direct markets that SOM operates in, assuming SOM can address at least 69% of CPAP users.

This Presentation: (i) contains summary information about SomnoMed and its subsidiaries (the **Group**) and their activities current as at the date of this Presentation; (ii) is for information purposes only and is not, and does not comprise all of the information which would be required to be disclosed in a prospectus, product disclosure statement or other offering document under Australian law or any other law and will not be lodged with the Australian Securities and Investments Commission (**ASIC**) or any foreign regulator; (iii) does not and will not form any part of any contract for the acquisition of shares; and (iv) should be read in conjunction with SomnoMed's other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange (**ASX**), which are available at www.asx.com.au.

Market and industry data

Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. None of the Group, its representatives or advisors have independently verified any such market or industry data provided by third parties or industry or general publications.

Not investment or financial product advice

This Presentation is not financial product or investment advice or a recommendation to acquire SomnoMed shares or accounting, legal or tax advice. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of the Group and the impact that different future outcomes might have on the Group. Information in this Presentation is not intended to be relied upon as advice to investors or potential investors and has been prepared without taking into account the objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and seek financial, legal and taxation advice appropriate to their jurisdiction. The Group is not licensed to provide financial product advice in respect of the acquisition of shares.

Financial data

All dollar values are in Australian dollars (A\$ or AUD) unless stated otherwise.

The Financial Information is presented in an abbreviated form insofar as it does not include all the presentation and disclosures, statements or comparative information as required by Australian Accounting Standards (**AAS**) and other mandatory professional reporting requirements applicable to general purpose financial reports prepared in accordance with the Corporations Act.